Fewer than 10 percent of people with hypertension had their blood sugar under control & fewer than 66 percent of diabetics ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...

Medtronic's Jason Fontana offers an update on next-generation Symplicity Spyral devices, procedures and a new feature they're ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

There’s mixed evidence that garlic may help lower blood pressure. However, it may not be an effective treatment option for ...

Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as ...

Eating Swiss cheese can help lower your blood pressure because it is low in salt, high in calcium, low in calories, and has ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients with uncontrolled or treatment-resistant hypertension, AstraZeneca ...

Baxdrostat is an investigational highly selective, oral, small molecule designed to inhibit aldosterone synthase.

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.